Skip Navigation LinksHome > January 3, 2005 - Volume 19 - Issue 1 > Antiretroviral therapy with tenofovir is associated with mil...
AIDS:
Research Letter

Antiretroviral therapy with tenofovir is associated with mild renal dysfunction

Mauss, Stefan; Berger, Florian; Schmutz, Guenther

Free Access
Article Outline
Collapse Box

Author Information

Center for HIV and Hepatogastroenterology, Duesseldorf; Germany

Received 7 July, 2004

Revised 15 August, 2004

Accepted 1 September, 2004

Sponsorship: This study was supported by an unrestricted grant from Gilead Sciences, Martinsried, Germany.

Collapse Box

Abstract

A cross-sectional study was conducted to compare patients treated with tenofovir with patients never treated with tenofovir. Patients on tenofovir showed a lower mean glomerular filtration rate estimated by creatinine clearance or cystatin C clearance compared with control patients. In total, 24 patients on tenofovir versus five control patients had proteinuria greater than 130 mg/day. In the majority of patients on tenofovir proteinuria was of tubular origin.

Tenofovir disoproxil fumarate (tenofovir) shares some of its molecular structure with adefovir, a nucleotide analogue that is limited in its clinical use by nephrotoxicity [1,2]. In particular, a dose and time-dependent development of a Fanconi-like syndrome was reported [3]. In contrast, tenofovir has not shown overt nephrotoxic effects in clinical trials [4,5]. However, Fanconi's syndrome and renal failure induced by tenofovir has been reported in anecdotal cases after tenofovir was granted approval for the treatment of HIV infection [6–10]. In the present cross-sectional study we assessed the effect of tenofovir on glomerular and tubular renal function.

Patients treated with tenofovir (n = 82) were compared with patients on antiretroviral therapy never treated with tenofovir (n = 92) (Table 1). From each patient a blood sample was drawn, blood pressure was measured and 24-h urine was collected. Diabetes mellitus, hypertension as defined as systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg, liver cirrhosis or known renal disease were exclusion criteria.

Table 1
Table 1
Image Tools

Creatinine, urea, uric acid, cystatin C, sodium, potassium, calcium, phosphate and chloride were measured in serum. In urine collected over 24-h the excretion rate of total protein, creatinine, urea, uric acid, sodium, potassium, calcium, phosphate and chloride was analysed.

The glomerular filtration rate (GFR) was calculated on the basis of creatinine in urine collected over 24 h [11] or using serum cystatin C, a cationic low molecular weight (13 360 Mr) cysteine proteinase, which is an established renal clearance marker [12,13]. In addition, GFR was estimated using the modified Modification of Diet in Renal Disease Study (MDRD) formula: 186 × serum creatinine (mg/dl)−1.154 × age (years)−0.203 × 1.212 if black ×0.742 if female, which gives a normal range of 90–120 ml/min 1.73 m2 [14,15].

In the case of proteinuria greater than 130 mg/day a DISC-electrophoresis was performed to differentiate the origin of proteinuria. An increase in small molecules such as beta-2-microglobulin or alpha-1-microglobulin indicates tubular dysfunction and an increase in larger molecules such as immunoglobulin G, albumin or transferrin indicates glomerular dysfunction.

Statistical analysis was based on contingency tables. In addition a two-way analysis of variance with factors tenofovir and the previous use of indinavir including interactions was performed on different dependent variables (age, time on antiretroviral agents, sex). For computation SAS was used (The SAS System; SAS Institute, Cary, NC, USA).

Patients on tenofovir showed a lower mean GFR calculated by creatinine clearance (97 ± 49 ml/min 1.73 m2) or cystatin C clearance (86 ± 21 ml/min 1.73 m2) compared with control patients (107 ± 39 ml/min 1.73 m2) and (97 ± 20 ml/min 1.73 m2) (P < 0.05). An impaired GFR as estimated by creatinine clearance (normal range >90 ml/ml 1.73 m2) or cystatin C (normal range >80 ml/min 1.73 m2) was observed in 38 (46%) or 28 (34%) patients on tenofovir compared with 29 (32%) or 19 (21%) control patients (P = 0.04 for creatinine, P = 0.06 for cystatin C).

Creatinine clearance, as estimated by the MDRD formula based on serum creatinine, was not different in both groups (tenofovir 106 ± 54 ml/min 1.73m2 versus control 104 ± 22 ml/min 1.73m2, P = 0.375).

Patients on tenofovir had a higher mean protein content in urine (124 ± 110 versus 94 ± 55 mg/day, P = 0.03). In total, 24 patients on tenofovir (30%) versus five control patients (5%) had proteinuria greater than 130 mg/day (P < 0.001). The majority of patients showed a tubular pattern (14/24 versus 3/5). Combined tubular and glomerular proteinuria was found in seven out of 24 patients on tenofovir compared with one out of five control patients. A glomerular pattern was observed in three out of 24 patients on tenofovir and in one out of five control patients.

The excretion rate in urine of creatinine, urea, uric acid, sodium, potassium, calcium, phosphate and chloride were in the normal range and were not significantly different between both groups.

In the analysis of variance no association was found between an impaired GFR or proteinuria and sex, age, previous use of indinavir or time on antiretroviral drugs.

In one patient with marked proteinuria (170 mg/day), proteinuria was reversible after the discontinuation of tenofovir with a decrease to 93 mg/day 3 weeks after stopping.

No patient in the study fulfilled the criteria for nephrotic syndrome or Fanconi-like syndrome.

In conclusion, treatment with tenofovir was associated with a lower mean GFR as estimated by creatinine clearance or serum cystatin C. It has to be noted, however, that the mean GFR was still within the normal range. In addition, there was a higher number of patients with a pathological GFR calculated by creatinine clearance or cystatin C in the tenofovir group compared with control patients. Interestingly, these differences were not detected by creatinine clearance as calculated on the basis of serum creatinine using the MDRD formula. This method was recently used in some reports on the effect of tenofovir on renal function [16].

In addition, in the tenofovir-treated group an increased number of patients with significant proteinuria predominantly of tubular origin were observed. This pattern may support a mechanism related to the nephrotoxic effect of adefovir, which was also associated with tubular renal dysfunction. It has to be noted, however, that in contrast to the findings reported for adefovir [2,17] no enhanced renal loss of electrolytes was found in patients treated with tenofovir.

Other factors, such as exposure to indinavir, an antiretroviral agent with known nephrotoxic potential, time on antiretroviral drugs, sex or age did not change the association between tenofovir and a decreased GFR or proteinuria.

It has to be noted that the study is limited by its cross-sectional design, and prospective controlled studies are needed to confirm the observations. However, the value of this study is the application of sensitive markers of renal function. Mild nephrotoxic effects may be missed by the simple and convenient approach of the formula-based estimation of creatinine clearance based on serum creatinine and patient demographics.

In conclusion, treatment with tenofovir may induce mild renal dysfunction in a higher proportion of patients compared with patients never treated with tenofovir. Treatment with tenofovir may render the kidney more vulnerable to concomitant treatment with nephrotoxic drugs. Therefore, a detailed functional assessment of renal function should be included in the design of future trials including treatment with tenofovir.

Back to Top | Article Outline

References

1. Fisher EJ, Chaloner K, Cohn DL, Grant LB, Alston B, Brosgart CL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001; 15:1695–1700.

2. ADHOC International Steering Committee. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Med 2002, 324:342–344.

3. Hannon H, Bagnis CI, Benhamou Y, Beaufils H, Sullivan M, Brosgart C, et al. The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrol Dial Transplant 2004; 19:386–390.

4. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al, and the Study 902 team. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257–1263.

5. Cheng AK, Chen SS, Wulfsohn M, Toole JJ. 2 year long term safety profile of tenofovir DF (TDF) in treatment-experienced patients from randomized, double-blind, placebo-controlled clinical trials. In: 9th European AIDS Conference (EACS). Warsaw, Poland, 2003 [poster number 7.3/7].

6. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40:1331–1333.

7. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070–1073.

8. Murphy MD, O’Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003; 36:1082–1085.

9. Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:e41–e43.

10. James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004; 24:415–418.

11. Rapoport A, Husdan H. Endogenous creatinine clearance and serum creatinine in the clinical assessment of renal function. Can Med Assoc J 1968; 99:149–156.

12. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40:221–226.

13. Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F. Serum cystatin C reliably detects renal dysfunction in patients with various diseases. Nephron 2002; 91:13–20.

14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate GFR from serum creatinine: a new prediction equation. Modification of diet in renal disease group. Ann Intern Med 1999; 130:461–470.

15. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2000; 11:A0828.

16. Harris M, Zalunardo N, Bonner S, Werb R, Valyi M, Montaner JSG. Use of estimated glomerular filtration rate to predict renal toxicity in patients receiving tenofovir DF. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 2003 [poster 750].

17. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Min Res 2004; 19:714–721.

Cited By:

This article has been cited 48 time(s).

Antiviral Therapy
Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK
Schmid, H; Muhlbayer, D; Roling, J; Sternfeld, T; Julg, B; Schlattner, U; Nelson, PJ; Bogner, JR; Wallimann, T; Goebel, FD
Antiviral Therapy, 11(8): 1071-1080.

Hiv Medicine
Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy
Buchacz, K; Brooks, JT; Tong, T; Moorman, AC; Baker, RK; Holmberg, SD; Greenberg, A
Hiv Medicine, 7(7): 451-456.

Journal of Hepatology
Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management
Mauss, S
Journal of Hepatology, 44(): S114-S118.
10.1016/j.jhep.2005.11.024
CrossRef
Hiv Medicine
Comparison of glomerular filtration rate estimates vs. 24-h creatinine clearance in HIV-positive patients
Ravasi, G; Lauriola, M; Tinelli, C; Brandolini, M; Uglietti, A; Maserati, R
Hiv Medicine, 10(4): 219-228.
10.1111/j.1468-1293.2008.00673.x
CrossRef
AIDS
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
Nelson, MR; Katlama, C; Montaner, JS; Cooper, DA; Gazzard, B; Clotet, B; Lazzari, A; Schewe, K; Lange, J; Wyatt, C; Curtis, S; Chen, SS; Smith, S; Bischofberger, N; Rooney, JF
AIDS, 21(): 1273-1281.

Seminars in Nephrology
Antiretroviral Nephrotoxicities
Atta, MG; Deray, G; Lucas, GM
Seminars in Nephrology, 28(6): 563-575.
10.1016/j.semnephrol.2008.08.009
CrossRef
Clinical Infectious Diseases
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy
Reid, A; Stoehr, W; Walker, AS; Williams, IG; Kityo, C; Hughes, P; Kambugu, A; Gilks, CF; Mugyenyi, P; Munderi, P; Hakim, J; Gibb, DM
Clinical Infectious Diseases, 46(8): 1271-1281.
10.1086/533468
CrossRef
Clinical Infectious Diseases
HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy
Roling, J; Schmid, H; Fischereder, M; Draenert, R; Goebel, FD
Clinical Infectious Diseases, 42(): 1488-1495.

AIDS
Progression of renal impairment under therapy with tenofovir
Julg, BD; Bogner, JR; Crispin, A; Goebel, FD
AIDS, 19(): 1332-1333.

Antimicrobial Agents and Chemotherapy
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: Summary of pharmacokinetics and biological and virological effects
Van Rompay, KKA; Durand-Gasselin, L; Brignolo, LL; Ray, AS; Abel, K; Cihlar, T; Spinner, A; Jerome, C; Moore, J; Kearney, BP; Marthas, ML; Reiser, H; Bischofberger, N
Antimicrobial Agents and Chemotherapy, 52(9): 3144-3160.
10.1128/AAC.00350-08
CrossRef
Clinical Pharmacokinetics
Antiretroviral therapy - Pharmacokinetic considerations in patients with renal or hepatic impairment
McCabe, SM; Ma, Q; Slish, JC; Catanzaro, LM; Sheth, N; DiCenzo, R; Morse, GD
Clinical Pharmacokinetics, 47(3): 153-172.

Drugs
Renal disease in patients with HIV infection - Epidemiology, pathogenesis and management
Fine, DM; Perazella, MA; Lucas, GM; Atta, MG
Drugs, 68(7): 963-980.

AIDS
Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir
Crane, HM; Kestenbaum, B; Harrington, RD; Kitahata, MM
AIDS, 21(): 1431-1439.

Hiv Clinical Trials
Clinically stable treatment-experienced adults receiving tenofovir and didanosine
Di Biagio, A; Beltrame, A; Cenderello, G; Ferrea, G; De Maria, A
Hiv Clinical Trials, 7(1): 10-15.

Hiv Medicine
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy
Winston, A; Amin, J; Mallon, PWG; Marriott, D; Carr, A; Cooper, DA; Emery, S
Hiv Medicine, 7(2): 105-111.

Clinical Infectious Diseases
Coccidioidomycosis in persons infected with HIV type 1
Ampel, NM
Clinical Infectious Diseases, 41(8): 1174-1178.

Antiviral Therapy
Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients
Mauss, S; Berger, F; Kuschak, D; Henke, J; Hegener, P; Wolf, E; Schauseil, S; Schmutz, G
Antiviral Therapy, 13(8): 1091-1095.

Hiv Medicine
Tenofovir-associated renal and bone toxicity
Woodward, CLN; Hall, AM; Williams, IG; Madge, S; Copas, A; Nair, D; Edwards, SG; Johnson, MA; Connolly, JO
Hiv Medicine, 10(8): 482-487.
10.1111/j.1468-1293.2009.00716.x
CrossRef
Antiviral Therapy
The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era
Gupta, SK; Smurzynski, M; Franceschini, N; Bosch, RJ; Szczech, LA; Kalayjian, RC
Antiviral Therapy, 14(4): 543-549.

Archives of Internal Medicine
Cystatin C level as a marker of kidney function in human immunodeficiency virus infection - The FRAM study
Odden, MC; Scherzer, R; Bacchetti, P; Szczech, LA; Sidney, S; Grunfeld, C; Shlipak, MG
Archives of Internal Medicine, 167(): 2213-2219.

Antiviral Therapy
Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy
Cote, HCF; Magil, AB; Harris, M; Scarth, BJ; Gadawski, I; Wang, N; Yu, E; Yip, B; Zalunardo, N; Werb, R; Hogg, R; Harrigan, PR; Montaner, JS
Antiviral Therapy, 11(1): 79-86.

Enfermedades Infecciosas Y Microbiologia Clinica
Assessment and management of kidney disease in the HIV-1-infected patient. A practical review
Domingo, P; Knobel, H; Gutierrez, F; Barril, G; Fulladosa, X
Enfermedades Infecciosas Y Microbiologia Clinica, 28(3): 185-198.
10.1016/j.eimc.2009.05.004
CrossRef
American Journal of Kidney Diseases
Cystatin C and creatinine in an HIV cohort: The Nutrition for Healthy Living Study
Jones, CY; Jones, CA; Wilson, IB; Knox, TA; Levey, AS; Spiegelman, D; Gorbach, SL; Van Lente, F; Stevens, LA
American Journal of Kidney Diseases, 51(6): 914-924.
10.1053/j.ajkd.2008.01.027
CrossRef
Antiviral Therapy
Maraviroc: pharmacokinetics and drug interactions
Abel, S; Back, DJ; Vourvahis, M
Antiviral Therapy, 14(5): 607-618.

Enfermedades Infecciosas Y Microbiologia Clinica
Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection
Vallecillo-Sanchez, G; Guelar-Grimberg, A; Gonzalez-Mena, A; Knobel-Freud, H
Enfermedades Infecciosas Y Microbiologia Clinica, 26(5): 316-317.

British Journal of Clinical Pharmacology
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers
Abel, S; Russell, D; Whitlock, LA; Ridgway, CE; Muirhead, GJ
British Journal of Clinical Pharmacology, 65(): 47-53.
10.1111/j.1365-2125.2008.03135.x
CrossRef
International Journal of Std & AIDS
The cost of antiretroviral drugs and influence on prescribing policies
Jones, R; Gazzard, B
International Journal of Std & AIDS, 17(8): 499-506.

AIDS Research and Human Retroviruses
Urinary beta(2)-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil furnarate
Gatanaga, H; Tachikawa, N; Kikuchi, Y; Teruya, K; Genka, I; Honda, M; Tanuma, J; Yazaki, H; Ueda, A; Kimura, S; Oka, S
AIDS Research and Human Retroviruses, 22(8): 744-748.

Journal of Antimicrobial Chemotherapy
Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study
Guaraldi, G; Roverato, A; Giovanardi, C; Ravera, F; Squillace, N; Orlando, G; Cappelli, G; Esposito, R; Palella, F
Journal of Antimicrobial Chemotherapy, 63(2): 374-379.
10.1093/jac/dkn499
CrossRef
Nephrology Dialysis Transplantation
Acute renal failure in HIV patients
Izzedine, H; Baumelou, A; Deray, G
Nephrology Dialysis Transplantation, 22(): 2757-2762.
10.1093/ndt/gfm404
CrossRef
Mayo Clinic Proceedings
HIV-1 infection and the kidney: An evolving challenge in HIV medicine
De Silva, TI; Post, FA; Griffin, MD; Dockrell, DH
Mayo Clinic Proceedings, 82(9): 1103-1116.

Journal of Infectious Diseases
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy
Izzedine, H; Hulot, JS; Villard, E; Goyenvalle, C; Dominguez, S; Ghosn, J; Valantin, MA; Lechat, P; Deray, G
Journal of Infectious Diseases, 194(): 1481-1491.

AIDS Reader
Renal safety of tenofovir disoproxil fumarate
Sax, PE; Gallant, JE; Klotman, PE
AIDS Reader, 17(2): 90-+.

AIDS Reader
Tenofovir Nephrotoxicity-The Disconnect Between Clinical Trials and Real-World Practice
Atta, MG; Fine, DM
AIDS Reader, 19(3): 118-119.

Pharmacogenomics
Pharmacogenetics of tenofovir treatment
Rodriguez-Novoa, S; Labarga, P; Soriano, V
Pharmacogenomics, 10(): 1675-1685.
10.2217/PGS.09.115
CrossRef
Hiv Medicine
The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy
Parsonage, MJ; Wilkins, EGL; Snowden, N; Issa, BG; Savage, MW
Hiv Medicine, 6(5): 341-346.

Expert Opinion on Drug Safety
Tenofovir-induced kidney injury
Gitman, MD; Hirschwerk, D; Baskin, CH; Singhal, PC
Expert Opinion on Drug Safety, 6(2): 155-164.
10.1517/14740338.6.2.155
CrossRef
Clinical Infectious Diseases
Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study
Rodriguez-Novoa, S; Labarga, P; Soriano, V; Egan, D; Albalater, M; Morello, J; Cuenca, L; Gonzalez-Pardo, G; Khoo, S; Back, D; Owen, A
Clinical Infectious Diseases, 48(): E108-E116.
10.1086/598507
CrossRef
Antiviral Therapy
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study
Fux, CA; Simcock, M; Wolbers, M; Bucher, HC; Hirschel, B; Oprovil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H
Antiviral Therapy, 12(8): 1165-1173.

Antiviral Therapy
Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration
Jaroszewicz, J; Wiercinska-Drapalo, A; Lapinski, TW; Prokopowicz, D; Rogalska, M; Parfieniuk, A
Antiviral Therapy, 11(5): 641-645.

AIDS
Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia
Mulenga, LB; Kruse, G; Lakhi, S; Cantrell, RA; Reid, SE; Zulu, I; Stringer, EM; Krishnasami, Z; Mwinga, A; Saag, MS; Stringer, JS; Chi, BH
AIDS, 22(14): 1821-1827.
10.1097/QAD.0b013e328307a051
PDF (279) | CrossRef
AIDS
Chronic renal failure among HIV-1-infected patients
Mocroft, A; Kirk, O; Gatell, J; Reiss, P; Gargalianos, P; Zilmer, K; Beniowski, M; Viard, J; Staszewski, S; Lundgren, JD; for the EuroSIDA Study Group,
AIDS, 21(9): 1119-1127.
10.1097/QAD.0b013e3280f774ee
PDF (162) | CrossRef
AIDS
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations
Soriano, V; Rodríguez-Nóvoa, S; Labarga, P; D'Avolio, A; Barreiro, P; Albalate, M; Vispo, E; Solera, C; Siccardi, M; Bonora, S; Di Perri, G
AIDS, 24(7): 1064-1066.
10.1097/QAD.0b013e32833202e2
PDF (301) | CrossRef
AIDS
Renal function with use of a tenofovir-containing initial antiretroviral regimen
Gallant, JE; Moore, RD
AIDS, 23(15): 1971-1975.
10.1097/QAD.0b013e32832c96e9
PDF (349) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Proteinuria and Endothelial Dysfunction in Stable HIV-Infected Patients: A Pilot Study
Gupta, SK; Mather, KJ; Agarwal, R; Saha, CK; Considine, RV; Dubé, MP
JAIDS Journal of Acquired Immune Deficiency Syndromes, 45(5): 596-598.
10.1097/QAI.0b013e318061d2fa
PDF (253) | CrossRef
AIDS Reader
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome
Brim, NM; Cu-Uvin, S; Hu, SL; O'Bell, JW
AIDS Reader, 17(6): 322-328.

Revue De Medecine Interne
Acute renal failure, Fanconi syndrome and insipidus diabetes in a HIV-infected patient treated with Tenofovir
Harmouche, H; Le Bras, P; Bignani, O; Delfraissey, JF; Goujard, C
Revue De Medecine Interne, 26(6): 522-523.
10.1016/j.revmed.2005.01.013
CrossRef
Antimicrobial Agents and Chemotherapy
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells
Vidal, F; Domingo, JC; Guallar, J; Saumoy, M; Cordobilla, B; de la Rosa, RS; Giralt, M; Alvarez, ML; Lopez-Dupla, M; Torres, F; Villarroya, F; Cihlar, T; Domingo, P
Antimicrobial Agents and Chemotherapy, 50(): 3824-3832.
10.1128/AAC.00437-06
CrossRef
Back to Top | Article Outline

© 2005 Lippincott Williams & Wilkins, Inc.

Login